Publications & Presentations

top of page

May 9, 2018

Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors

Vaccine | Herbert, et al.

February 7, 2018

Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine

Immunotherapy | Hardin et al.

June 8, 2019

New List IAmerican Society of Clinical Oncology - Clinical efficacy of vaccination with the autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccine in metastatic melanomatem

Journal of Clinical Oncology | Hickerson, et al.

June 16, 2018

American Society of Clinical Oncology - Prospective, randomized, double-blind, placebo controlled, Phase IIb trial of the TLPLDC vaccine to prevent recurrence in resected Stage III or IV melanoma patients

May 12, 2020

American Society of Clinical Oncology - Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.

Journal of Clinical Oncology | Chick, et al.

PUBLICATIONS & PRESENTATIONS

CONTACT US

We would love to hear from you. Tell us a little about yourself and we will reach out.

Elios Therapeutics, LLC
111 Smith Hines Road, Suite E

Greenville, SC 29607

bottom of page